__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Atherosclerotic cardiovascular disease

Cardiovascular disease is the leading cause of mortality worldwide, accounting for an estimated 18 million deaths per year.1

In Ireland, cardiovascular disease:

  • Is responsible for over a quarter (27.5%) of all deaths2
  • Causes more than 8,700 deaths each year2
  • It is a clinical priority for the HSE.3
 

Infographic of the Ireland map with text 'Cardiovascular disease is the leading cause of mortality worldwide, accounting for an estimated 18 million deaths per year.

The risk of developing cardiovascular disease can be reduced by addressing behavioural risk factors, such as:4

Blue box with blue image of a cigarette and 2-smoke lines with text saying 'Smoking'.
Blue box with blue image of shoe soles with a blue line striked through with text saying 'Physical Inactivity'.
Blue box with a scale icon with text saying 'Obesity'
Blue box an apple icon with a line going through it with text saying 'Unhealthy diet'
Blue box with a bottle and a glass icon with text saying 'Excessive alcohol consumption'
 

 

Other risk factors include:5–7

Blue box with a blue heart with ECG line going through it with text saying 'Hypertension'.
Blue box with globe icon with text saying 'High levels of Lp(a)
Blue box with globe icon with text saying 'High levels of Lp(a)
Blue box with blue hand with index finger raised up with text saying 'Diabetes'.
Blue box with tree icon with text saying 'Family history and ethnicity'.
 
Blue box with 50+ icon with text saying 'Being over the age of 50'.
Blue box with male gender icon with text saying ; Gender.
 

Atherosclerotic cardiovascular disease (ASCVD), a type of cardiovascular disease, that is caused by dyslipidaemia and the accumulation of lipoproteins within the arterial wall, leading to the formation of atherosclerotic plaques. These plaques grow due to continued accumulation of lipoproteins and the proliferation of smooth muscle and fibrous tissue. All these factors contribute to narrowing of the arteries, with subsequent plaque rupture and thrombosis.8 Depending on the location of the obstruction, this can cause a number of cardiovascular conditions, including: coronary heart disease, stroke, and peripheral arterial disease.9

Diagram showing dyslipidaemia and the accumulation of lipoproteins within the arterial wall, which leads to the formation of atherosclerotic plaques.

The risk of atherosclerotic cardiovascular disease is increased in patients with familial hypercholesterolaemia (FH) – a common autosomal inherited disorder affecting around one in 250 people in the Ireland.10,11 Individuals with  FH have a higher risk of premature ASCVD and death than the general population.10,12 FH is usually caused by mutations in the gene encoding the LDL receptor. As a result, the function of the LDL receptor is decreased and levels of LDL-C are abnormally high from birth.10  

Role of lipoproteins in atherosclerosis

The risk of experiencing an acute atherosclerotic cardiovascular disease event rises rapidly as more lipoproteins – for example: Low density Lipoprotein-C (LDL-C) and Lp(a) –  become retained and atherosclerotic plaque burden increases.13

Watch the video below to learn more about the consequences of long-term exposure to persistently elevated LDL-C.

LDL-C goals for primary and secondary prevention13

LDL-C-lowering interventions are recommended for both the primary prevention of atherosclerotic cardiovascular disease and the secondary prevention of recurrent cardiovascular events.

The 2019 ESC/EAS guidelines recommend a risk-based approach with more aggressive LDL-C goals for those at higher risk of ASCVD.13

Cardiovascular risk categories

 

Very-high-risk

  • ASCVD (clinical/imaging)
  • SCORE ≥10% for 10-year risk of fatal CVD
  • FH with ASCVD or with another major risk factor
  • Severe CKD (eGFR <30 mL/min)
  • DM and target organ damage, or ≥3 major risk factors; or early onset of T1DM of long duration (>20 years)
 

High-risk

  • SCORE ≥5% and <10% for 10-year risk of fatal CVD
  • Markedly elevated single risk factors, in particular TC >8 mmol/L (310 mg/dL) or LDL-C >4.9 mmol/L (190 mg/dL) or BP ≥180/110 mmHg
  • FH without other major risk factors
  • Moderate CKD (eGFR 30–59 mL/min)
  • DM without target organ damage, with DM duration ≥10 years or other additional risk factor
 

Moderate-risk

  • SCORE ≥1% and <5% for 10-year risk of fatal CVD
  • Young patients (T1DM <35 years; T2DM <50 years) with DM duration <10 years without other risk factors
 

Low-risk

  • Calculated SCORE <1% for 10-year risk of fatal CVD
 

Adapted from Mach F et al. 2020.13

 

LDL-C target value

Line graph showing LDL-C target value

Adapted from Mach F et al. 2020.13

 

For more information, refer to the guidelines here.

It is estimated that there are nearly 220,000 people with atherosclerotic cardiovascular disease in Ireland14

 

ApoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESC/EAS, European Society of Cardiology/European Atherosclerosis Society; FH, familial hypercholesterolaemia; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); SCORE, Systematic Coronary Risk Estimation; TC, total cholesterol; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus

References

  1. WHO. Cardiovascular diseases. Available at: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 .
  2. Central Statistics Office. Vital Statistics Yearly Summary May 2021. https://www.cso.ie/en/releasesandpublications/ep/p-vsys/vitalstatisticsy...
  3. HSE Chronic Disease Management Programme. Available at: https://www.hse.ie/eng/about/who/gmscontracts/2019agreement/chronic-dise...
  4. WHO. Cardiovascular diseases (CVDs). Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) .
  5. NHS. Cardiovascular disease. Available at: https://www.nhs.uk/conditions/cardiovascular-disease/ .
  6. Tsimikas S. J Am Coll Cardiol 2017;69:692–711.
  7. Tsimikas S et al. J Am Coll Cardiol 2018;71(2):177–192.
  8. IntechOpen. Dyslipidemia and its role in the pathogenesis of atherosclerotic cardiovascular disease: implications for evaluation and targets for treatment of dyslipidemia based on recent guidelines. Available at: https://www.intechopen.com/chapters/66725 .
  9. National Research Council (US) Committee on Diet and Health. Atherosclerotic Cardiovascular Diseases (19) in Diet and Health: Implications for Reducing Chronic Disease Risk, 1989. National Academies Press (US).
  10. Reiner Ž. Nat Rev Cardiol 2015;12(10):565–575.
  11. Croi. What is Familial Cholesterolaemia. https://croi.ie/health/heart?conditions/familial-hypercholesterolaemia/
  12. Hu P et al. Circulation 2020;141(22):1742–1759.
  13. Mach F et al. Eur Heart J 2020;41(1):111–188.
  14. EHN. European Heart Foundation European Cardiovascular Disease Statistics 2017. https://ehnheart.org/cvd-statistics/cvd-statistics-2017
April 2022 | IE 177598

Reporting of side effects
Adverse events (side effects) can be reported via the HPRA. Reporting forms and information can be found at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling (01) 2080 612. For information on any of our medicinal products please contact Medical Information on (01) 260 1255.

×

Ask Speakers

×

Medical Information Request